ECSP19072235A - Anticuerpos anti-ILT4 y fragmentos de unión a antígeno - Google Patents

Anticuerpos anti-ILT4 y fragmentos de unión a antígeno

Info

Publication number
ECSP19072235A
ECSP19072235A ECSENADI201972235A ECDI201972235A ECSP19072235A EC SP19072235 A ECSP19072235 A EC SP19072235A EC SENADI201972235 A ECSENADI201972235 A EC SENADI201972235A EC DI201972235 A ECDI201972235 A EC DI201972235A EC SP19072235 A ECSP19072235 A EC SP19072235A
Authority
EC
Ecuador
Prior art keywords
antigen
binding fragments
antibodies
ilt4 antibodies
ilt4
Prior art date
Application number
ECSENADI201972235A
Other languages
English (en)
Inventor
A Zuñiga Luis
Claudia Schuster Andrea
Schultze Kornelia
Blanusa Milan
Joyce-Shaikh Barbara
Original Assignee
Agenus Inc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc, Merck Sharp & Dohme filed Critical Agenus Inc
Publication of ECSP19072235A publication Critical patent/ECSP19072235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen a ILT4 (transcrito de tipo inmunoglobulina 4) y combinaciones de los mismos, por ejemplo, con un anticuerpo anti-PD1. También se proporcionan procedimientos de uso de los mismos, por ejemplo, para tratar o prevenir el cáncer en un sujeto; y procedimientos de preparación de dichos anticuerpos y fragmentos
ECSENADI201972235A 2017-04-07 2019-10-04 Anticuerpos anti-ILT4 y fragmentos de unión a antígeno ECSP19072235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483019P 2017-04-07 2017-04-07

Publications (1)

Publication Number Publication Date
ECSP19072235A true ECSP19072235A (es) 2019-12-27

Family

ID=62063229

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201972235A ECSP19072235A (es) 2017-04-07 2019-10-04 Anticuerpos anti-ILT4 y fragmentos de unión a antígeno

Country Status (27)

Country Link
US (4) US11053315B2 (es)
EP (1) EP3606958A1 (es)
JP (2) JP7045392B2 (es)
KR (1) KR102357823B1 (es)
CN (1) CN110719917A (es)
AR (1) AR111362A1 (es)
AU (3) AU2018248294B2 (es)
BR (1) BR112019021000A2 (es)
CA (1) CA3057378A1 (es)
CL (1) CL2019002855A1 (es)
CO (1) CO2019011155A2 (es)
CR (1) CR20190459A (es)
DO (1) DOP2019000253A (es)
EA (1) EA201992402A1 (es)
EC (1) ECSP19072235A (es)
GE (2) GEAP202215209A (es)
IL (1) IL269593A (es)
JO (1) JOP20190236B1 (es)
MX (1) MX392369B (es)
NI (1) NI201900103A (es)
PE (1) PE20191813A1 (es)
PH (1) PH12019502275A1 (es)
SG (1) SG11201909081YA (es)
TN (1) TN2019000272A1 (es)
TW (1) TWI796329B (es)
UA (1) UA126865C2 (es)
WO (1) WO2018187518A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
CA3104530A1 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
EP3827020A1 (en) * 2018-07-24 2021-06-02 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
WO2020061059A1 (en) * 2018-09-17 2020-03-26 Icahn School Of Medicine At Mount Sinai Anti-lilrb2 antibodies and methods of use thereof
JP2022521551A (ja) * 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
PH12022550333A1 (en) 2019-08-12 2023-06-14 Biond Biologics Ltd Antibodies against ilt2 and use thereof
CN112442527B (zh) * 2019-08-27 2022-11-11 深圳市英马诺生物科技有限公司 孤独症诊断试剂盒、基因芯片、基因靶点筛选方法及应用
CA3162311A1 (en) * 2019-12-20 2021-06-24 Philip E. Brandish Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
BR112022013143A2 (pt) * 2020-01-02 2022-09-20 Merck Sharp & Dohme Llc Tratamento de combinação contra câncer usando um antagonista de pd-1, um antagonista de ilt4 e lenvatinibe ou sais dos mesmos
WO2021158413A1 (en) * 2020-02-05 2021-08-12 The Board Of Regents Of The University Of Texas System Novel lilrb2 antibodies and uses thereof
CA3181197A1 (en) 2020-05-01 2021-11-04 NGM Biopharmaceuticals, Inc Ilt-binding agents and methods of use thereof
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도
KR20230069965A (ko) * 2020-09-17 2023-05-19 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 항-ilt4 항체 또는 그의 항-pd-1 항체와의 조합물의 투여 요법
KR20230093010A (ko) * 2020-10-21 2023-06-26 이뮨-온크 테라퓨틱스, 인코포레이티드 신규 항-lilrb2 항체 및 유도체 생성물
WO2022217019A1 (en) * 2021-04-09 2022-10-13 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
AU2022322029A1 (en) 2021-08-05 2024-02-15 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
ES3048791T3 (en) 2021-08-05 2025-12-11 Immunos Therapeutics Ag Pharmaceutical compositions comprising hla fusion proteins
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023114346A2 (en) * 2021-12-16 2023-06-22 Merck Sharp & Dohme Llc Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy
US20250197491A1 (en) 2022-03-11 2025-06-19 Macomics Limited Compositions and methods for modulation of macrophage activity
CN119095876A (zh) * 2022-03-28 2024-12-06 科赫鲁斯生物科学有限公司 抗ilt4组合物和方法
KR20250006250A (ko) * 2022-04-29 2025-01-10 머크 샤프 앤드 돔 엘엘씨 항-pd-1 항체와 조합된 항-ilt4 항체 또는 그의 항원-결합 단편의 안정한 제제 및 그의 사용 방법
JP2025515325A (ja) * 2022-04-29 2025-05-14 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｉｌｔ４抗体又はその抗原結合フラグメントの医薬製剤及び使用方法
TW202409088A (zh) * 2022-07-08 2024-03-01 中國商科望（蘇州）生物醫藥科技有限公司 抗lilrb2抗體及其用途
CN119604531A (zh) * 2022-07-29 2025-03-11 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
CN119768432A (zh) * 2022-08-22 2025-04-04 德琪(杭州)生物有限公司 新颖的抗lilrb2抗体和其用途
TW202413414A (zh) 2022-09-08 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌｔ４抗體及其醫藥用途
EP4628508A1 (en) 2022-12-09 2025-10-08 Biodlink Biopharm Co., Ltd. Anti-ilt4 antibody as well as preparation method therefor and use thereof
JP2025542200A (ja) * 2022-12-23 2025-12-25 イオックス セラピューティクス アーゲー 白血球免疫グロブリン様受容体サブファミリーＢｌ（ＬＩＬＢ１）及びＬＩＬＢ２を標的とする交差特異的抗原結合タンパク質（ＡＢＰ）、その組合せ及び使用
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
EP4662230A1 (en) 2023-02-08 2025-12-17 ImmunOs Therapeutics AG Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa
CN117925759B (zh) * 2024-01-23 2024-07-02 通化康元生物科技有限公司 林蛙多肽制剂及其在食品和化妆品中的应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6998267B1 (en) 1998-12-09 2006-02-14 The Dow Chemical Company Method for manufacturing glycoproteins having human-type glycosylation
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002345878A1 (en) 2001-06-25 2003-01-08 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
AU2002360376B2 (en) 2001-11-14 2006-05-18 Immunex Corporation Modulation of LIR function to treat rheumatoid arthritis
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
DE102004034416A1 (de) 2004-07-15 2006-02-02 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Flüssige, strahlunghärtende Zusammensetzungen
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
TW201247700A (en) 2011-05-05 2012-12-01 Baylor Res Inst Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
EP3421601B1 (en) 2011-12-30 2019-12-04 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
US9944685B2 (en) 2012-07-02 2018-04-17 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
WO2014103534A1 (ja) 2012-12-28 2014-07-03 国立大学法人大阪大学 コラーゲン結合性分子を付加した改変ラミニンおよびその利用
EP2970373A1 (en) * 2013-03-12 2016-01-20 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
WO2015179633A1 (en) * 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016044022A1 (en) 2014-09-16 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AU2016218900A1 (en) 2015-02-11 2017-08-24 University Health Network Methods and compositions for modulating LILR proteins
AU2016229201B2 (en) * 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
WO2018013534A1 (en) 2016-07-11 2018-01-18 Dana-Farber Cancer Institute, Inc. Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
US11906519B2 (en) 2016-07-29 2024-02-20 The Board Of Regents Of The University Of Texas System Methods for identifying LILRB-blocking antibodies
AU2017307610B2 (en) 2016-08-04 2023-10-05 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
AU2017313917B2 (en) 2016-08-18 2023-12-21 The Regents Of The University Of California CRISPR-Cas genome engineering via a modular AAV delivery system
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP2019530456A (ja) 2016-09-28 2019-10-24 ガビッシュ−ガリラヤ バイオ アプリケーションズ リミテッド 癌の新規抗原性シグネチャーを標的としたｃａｒ療法のためのユニバーサルプラットフォーム
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
CA3104530A1 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4

Also Published As

Publication number Publication date
BR112019021000A2 (pt) 2020-05-05
US12344670B2 (en) 2025-07-01
PH12019502275A1 (en) 2020-09-21
CO2019011155A2 (es) 2019-10-21
JOP20190236B1 (ar) 2023-09-17
KR20190136064A (ko) 2019-12-09
EA201992402A1 (ru) 2020-02-19
US11053315B2 (en) 2021-07-06
WO2018187518A1 (en) 2018-10-11
JP7045392B2 (ja) 2022-03-31
SG11201909081YA (en) 2019-10-30
AU2021225143A1 (en) 2021-09-30
DOP2019000253A (es) 2019-12-15
AR111362A1 (es) 2019-07-03
TW201839014A (zh) 2018-11-01
NI201900103A (es) 2019-10-31
US20240228614A1 (en) 2024-07-11
UA126865C2 (uk) 2023-02-15
AU2018248294A1 (en) 2019-10-10
GEP20227440B (en) 2022-11-25
CA3057378A1 (en) 2018-10-11
US20220033496A1 (en) 2022-02-03
JP2022084773A (ja) 2022-06-07
GEAP202215209A (en) 2022-07-11
US20180298096A1 (en) 2018-10-18
CL2019002855A1 (es) 2020-02-21
TN2019000272A1 (en) 2021-01-07
IL269593A (en) 2019-11-28
AU2018248294B2 (en) 2021-08-05
US11897956B2 (en) 2024-02-13
EP3606958A1 (en) 2020-02-12
MX2019011927A (es) 2020-02-10
MX392369B (es) 2025-03-24
TWI796329B (zh) 2023-03-21
US20220002403A1 (en) 2022-01-06
AU2024278314A1 (en) 2025-01-09
PE20191813A1 (es) 2019-12-26
JP7394160B2 (ja) 2023-12-07
CR20190459A (es) 2020-02-14
JOP20190236A1 (ar) 2019-10-06
US11897957B2 (en) 2024-02-13
CN110719917A (zh) 2020-01-21
KR102357823B1 (ko) 2022-01-28
JP2020519235A (ja) 2020-07-02

Similar Documents

Publication Publication Date Title
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
MX2017001597A (es) Anticuerpos anti-pd-l1.
BR112016030740A2 (pt) diacorpos heterodiméricos biespecíficos e seus usos
CL2017000250A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.